Registration is now closed, as this program has already taken place.
Friday, 15 June 2018

Welcome Reception & Hors d'oeuvres
17:00 – 17:30
Panel Discussion and Audience Q&A
17:30 – 19:00

RAI Amsterdam
Forum Room
Europaplein
NL 1078 GZ Amsterdam
Netherlands

PROGRAM AGENDA
17:00 – 17:30 Welcome Reception & Hors d'oeuvres
17:30 – 17:40 Welcome and Introductions
  Paul Emery, MA, MD, FRCP, FMedSci
17:40 – 18:00 Panel Discussion: The Patient with RA Who Fails to Respond
  All Faculty
18:00 – 18:05 Q&A Session
  Faculty and Audience
18:05 – 18:25 Panel Discussion: The Patient with RA Who Becomes Non-responsive
  All Faculty
18:25 – 18:30 Q&A Session
  Faculty and Audience
18:30 – 18:50 Panel Discussion: The Patient with Poor Response and Comorbidities
  All faculty
18:50 – 18:55 Q&A Session
  Faculty and Audience
18:55 – 19:00 Concluding Remarks
  Paul Emery, MA, MD, FRCP, FMedSci

FACULTY

Paul Emery, MA, MD, FRCP, FMedSci (Chair)
Arthritis Research UK Professor of Rheumatology
Leeds Institute of Rheumatic & Musculoskeletal Medicine, University of Leeds
Director, Leeds Biomedical Research Centre
Leeds Teaching Hospitals NHS Trust
Leeds, England (UK)

Jonathan Kay, MD
Professor of Medicine
Timothy S. and Elaine L. Peterson Chair in Rheumatology
Director of Clinical Research, Division of Rheumatology
University of Massachusetts Medical School
Worcester, Massachusetts (USA)

Josef S. Smolen, MD
Professor of Medicine
Chairman, Division of Medicine and Department of Medicine 3
Medical University of Vienna
Vienna, Austria (Europe)

TARGET AUDIENCE
This activity has been designed to meet the educational needs of clinicians involved in the care of patients with rheumatoid arthritis (RA).

EDUCATIONAL OBJECTIVES
After completing this activity, the participant will demonstrate the ability to:

  • Describe involvement of the IL-6 signaling pathway in the pathophysiology, extra-articular symptomology, and associated comorbidities of rheumatoid arthritis (RA), and the role of cytokine-targeted therapy in the treatment of RA
  • Incorporate validated and guideline-recommended RA disease activity monitoring to guide appropriate management of patients
  • Use a treat-to-target approach for managing RA that personalizes therapy by cycling or switching treatment options in nonresponsive patients, and takes into account data for new and emerging biologic and targeted synthetic DMARDs
  • Develop individualized RA treatment strategies that incorporate patient preferences, shared decision making, and patient education

ACCREDITATION STATEMENT
An application has been made to the UEMS EACCME® for CME accreditation of this event.

DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

FEE INFORMATION
There is no fee for this educational activity.

PROVIDER STATEMENT
Jointly provided by RMEI Medical Education, LLC and Postgraduate Institute for Medicine.

FUNDING SUPPORT
This symposium is supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

 

FOLLOW RMEI

Facebook Twitter


Additional educational activities offered by RMEI Medical Education, LLC can be found at www.RMEI.com or by calling toll-free (866) 770-RMEI.